Legato Capital Management LLC Purchases 9,760 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Legato Capital Management LLC raised its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 122.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,755 shares of the company’s stock after purchasing an additional 9,760 shares during the period. Legato Capital Management LLC’s holdings in Tarsus Pharmaceuticals were worth $1,454,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Comerica Bank increased its stake in Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after purchasing an additional 705 shares in the last quarter. Leonteq Securities AG bought a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $164,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Tarsus Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock worth $169,000 after acquiring an additional 431 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Tarsus Pharmaceuticals by 779.1% during the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after acquiring an additional 2,462 shares in the last quarter. Finally, Valeo Financial Advisors LLC bought a new stake in shares of Tarsus Pharmaceuticals during the third quarter worth $209,000. Institutional investors own 90.01% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TARS. The Goldman Sachs Group reissued a “neutral” rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. HC Wainwright reissued a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Oppenheimer began coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They set an “outperform” rating and a $98.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.67.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, Director William J. Phd Link sold 12,500 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $68.79, for a total value of $859,875.00. Following the completion of the transaction, the director owned 116,332 shares of the company’s stock, valued at approximately $8,002,478.28. This trade represents a 9.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Bryan Wahl sold 4,231 shares of the firm’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $283,477.00. Following the completion of the transaction, the general counsel directly owned 63,959 shares of the company’s stock, valued at approximately $4,285,253. This trade represents a 6.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 79,391 shares of company stock worth $5,432,035 in the last three months. 9.64% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock opened at $62.26 on Monday. The firm has a fifty day moving average of $66.07 and a 200-day moving average of $71.39. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 12-month low of $38.51 and a 12-month high of $85.25. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of -54.61 and a beta of 0.52.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. The business had revenue of $162.05 million during the quarter, compared to the consensus estimate of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. As a group, equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.